Tag: leqvio market analysis

Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.

Leqvio Market Forecast: What Value Will The Market Reach By 2030?

The historical growth can be linked to a rising incidence of hyperlipidemia, alongside progress in RNA interference technology, the proliferation of cardiovascular specialty clinics, increasing public understanding of LDL cholesterol management, and enhancements in injectable drug delivery systems.

Anticipated growth throughout the forecast period is primarily driven by the increasing integration of innovative RNA therapeutics, a heightened concentration on reducing cardiovascular risks, the widening availability of extended-interval dosing treatments, escalating financial commitments to cardiometabolic research, and an increased requirement for long-lasting lipid-reducing interventions.

Significant trends expected during the projection period encompass the broadening uptake of siRNA-based lipid-lowering therapies, a surging need for cardiovascular treatments offering prolonged effects, an intensifying focus on proactive cardiac care strategies, the proliferation of sophisticated RNA manufacturing technologies, and a stronger emphasis on improving patient compliance.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=97271042&type=smp&name=Leqvio%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Leqvio Market Demand Drivers Opening New Revenue Streams

The increasing geriatric demographic is anticipated to stimulate the demand for leqvio in the future. This population segment comprises individuals typically 65 years of age and older. Significant improvements in healthcare and medical technology have substantially extended life expectancy, thereby contributing to the expansion of the geriatric population. Leqvio is effective in lowering LDL cholesterol, which simplifies medication adherence for older adults. Its prolonged action lessens cardiovascular risks, leading to improved health outcomes within the geriatric population. For instance, in January 2024, data from the Population Reference Bureau, a Kenya-based nonprofit organization, indicated that the number of Americans aged 65 and above is projected to rise from 58 million in 2022 to 82 million by 2050, representing a 47% increase. Concurrently, this age group’s proportion of the total population is also forecasted to increase from 17% to 23% over the same timeframe. Consequently, the expanding geriatric population is a key factor propelling the growth of the leqvio market.

Leqvio Market Segmentation And Category Overview

The leqvio market covered in this report is segmented –

1) By Formulation: Injectable Formulation (Subcutaneous), Pre-Filled Syringes Or Auto-Injectors

2) By Indication: Treatment Of Hyperlipidemia, Management Of Atherosclerotic Cardiovascular Disease (ASCVD), Treatment Of Familial Hypercholesterolemia

3) By Patient Demographics: Adult Patients, Geriatric Patients, Patients with Comorbid Conditions

4) By Distribution Channel: Direct Sales, Wholesalers and Distributors, Retail Pharmacies, Online Pharmacies

5) By End-User: Hospitals, Cardiovascular Clinics, Specialty Pharmacies, Home Healthcare Providers

Leqvio Market Trends Powering Strategic Industry Growth

Major companies are actively involved in the Leqvio market, concentrating on developing advanced injectable prescription medications such as Label Expansion to enhance therapeutic accessibility and facilitate early intervention. Label Expansion refers to the regulatory authorization provided by bodies like the FDA, which allows an already approved drug to be used for additional indications, patient groups, or clinical settings beyond its original authorized application. For example, in July 2023, Novartis AG, a pharmaceutical company based in Switzerland, received US Food and Drug Administration (FDA) approval for a label update for Leqvio (inclisiran). This update enables its use at an earlier stage for patients with elevated LDL-C and an increased risk of heart disease, in addition to diet and statin therapy. After two initial doses, it is administered two times per year, providing up to a 52% LDL-C reduction, and has been proven effective for patients unable to reach their LDL-C target despite statin therapy. The label update emphasizes robust safety and efficacy data, corroborated by the VictORION clinical trial program.

Leqvio Market Competitive Analysis Of Leading Industry Participants

Major companies operating in the leqvio market are Novartis AG

View The Full Leqvio Market Report:

https://thebusinessresearchcompany.com/report/leqvio-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Leqvio Market Top Region By Revenue And Market Share

North America was the largest region in the leqvio market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the leqvio market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.

Leqvio Market Growth Potential: How Will Market Size Change Through 2030?

The expansion observed during the historic period was fueled by a rising incidence of hyperlipidemia, progress in RNA interference approaches, a broader network of cardiovascular specialty facilities, heightened consciousness around controlling LDL cholesterol levels, and enhanced systems for administering injectable medications.

The expansion observed in the forecast period is driven by the growing uptake of innovative RNA therapeutics, a heightened focus on mitigating cardiovascular risks, the broader rollout of therapies with extended dosing intervals, rising financial commitments to cardiometabolic studies, and the escalating need for long-lasting lipid-reduction options. Key developments shaping this period encompass the rising use of siRNA-based strategies for lowering lipids, an increased appetite for durable cardiovascular interventions, a stronger orientation toward preventive cardiology approaches, the advancement of sophisticated RNA production techniques, and a greater priority placed on improving patient compliance with treatment regimens.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20143&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

#Leqvio Market Growth Factors: Which Forces Are Supporting Market Expansion?

The rising number of older adults is anticipated to drive future demand for leqvio. This demographic is typically made up of individuals who are 65 years old or older. Improvements in healthcare and medical technologies have substantially increased life expectancy, which in turn has fueled the expansion of the elderly population. By lowering LDL cholesterol, leqvio simplifies medication management for seniors. Its prolonged effectiveness helps reduce the risk of cardiovascular events, thereby improving health outcomes among the geriatric group. For example, in January 2024, the Population Reference Bureau, a nonprofit organization based in Kenya, reported that the number of Americans aged 65 and above is forecast to grow from 58 million in 2022 to 82 million by 2050—a rise of 47%. During the same timeframe, this age bracket’s proportion of the total U.S. population is expected to increase from 17% to 23%. Consequently, the expanding geriatric population is fueling growth in the leqvio market.

Leqvio Market Segment Analysis And Revenue Opportunities

The leqvio market covered in this report is segmented –

1) By Formulation: Injectable Formulation (Subcutaneous), Pre-Filled Syringes Or Auto-Injectors

2) By Indication: Treatment Of Hyperlipidemia, Management Of Atherosclerotic Cardiovascular Disease (ASCVD), Treatment Of Familial Hypercholesterolemia

3) By Patient Demographics: Adult Patients, Geriatric Patients, Patients with Comorbid Conditions

4) By Distribution Channel: Direct Sales, Wholesalers and Distributors, Retail Pharmacies, Online Pharmacies

5) By End-User: Hospitals, Cardiovascular Clinics, Specialty Pharmacies, Home Healthcare Providers

Leqvio Market Industry Trends: What Changes Are Reshaping Demand?

Major players in the leqvio market are actively working on the development of advanced injectable prescription medicines, such as Label Expansion, which aims to improve therapeutic accessibility and facilitate early intervention. Label Expansion involves receiving regulatory permission from bodies like the FDA to broaden the use of an already approved drug for new indications, different patient populations, or alternative clinical settings beyond its initial authorization. For example, in July 2023, Novartis AG, a pharmaceutical firm based in Switzerland, secured approval from the US Food and Drug Administration (FDA) for a revised label for Leqvio (inclisiran), enabling its earlier application in patients with elevated LDL-C and heightened cardiovascular risk, alongside dietary modifications and statin therapy. Administered as two doses annually after an initial two-dose regimen, it achieves up to a 52% reduction in LDL-C and has demonstrated efficacy in patients who fail to meet their LDL-C objectives despite statin use. This label update is supported by strong safety and efficacy results from the VictORION clinical trial program.

Leqvio Market Leading Players Shaping Industry Direction

Major companies operating in the leqvio market are Novartis AG

Access The Complete Leqvio Market Report:

https://www.thebusinessresearchcompany.com/report/leqvio-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Leqvio Market Global Footprint: Which Region Holds Market Leadership?

North America was the largest region in the leqvio market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the leqvio market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

How Much Larger Will The Leqvio Market Become By 2030 Compared To 2026?

Historically, this growth is primarily linked to the rising occurrence of hyperlipidemia, breakthroughs in RNA interference technology, the proliferation of cardiovascular specialty clinics, heightened understanding of LDL cholesterol management, and enhancements in injectable drug delivery systems.

The anticipated expansion during the projected timeframe stems from the wider acceptance of innovative RNA-based treatments, a heightened emphasis on mitigating cardiovascular risks, the proliferation of therapies requiring less frequent administration, escalating financial commitments to cardiometabolic studies, and a greater need for lasting solutions to reduce lipids.

Key developments expected during the forecast period encompass the growing embrace of siRNA-based treatments for lipid reduction, a surge in demand for cardiovascular therapies with extended effects, an intensified attention on proactive heart health interventions, the broadening of sophisticated RNA production methods, and an increased priority placed on improving patient compliance with treatments.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20143&type=smp

What Key Growth Drivers Are Influencing The Leqvio Market?

The increasing number of older adults is anticipated to fuel the demand for leqvio in the future. This demographic comprises people generally aged 65 years and older. Significant progress in healthcare and medical technology has notably extended life expectancy, thus expanding the geriatric demographic. Leqvio helps reduce LDL cholesterol, simplifying medication routines for senior citizens. Its prolonged action diminishes cardiovascular hazards, thereby improving health results among the elderly. For example, data from January 2024, provided by the Population Reference Bureau, a Kenya-based nonprofit, indicates that the count of Americans aged 65 and above is projected to rise from 58 million in 2022 to 82 million by 2050, representing a 47% increase. Concurrently, this cohort’s proportion of the total population is forecast to increase from 17% to 23% within the same timeframe. Consequently, the expanding geriatric population is a key catalyst for the leqvio market’s expansion.

What Key Segment Areas Are Included In The Leqvio Market Assessment?

The leqvio market covered in this report is segmented –

1) By Formulation: Injectable Formulation (Subcutaneous), Pre-Filled Syringes Or Auto-Injectors

2) By Indication: Treatment Of Hyperlipidemia, Management Of Atherosclerotic Cardiovascular Disease (ASCVD), Treatment Of Familial Hypercholesterolemia

3) By Patient Demographics: Adult Patients, Geriatric Patients, Patients with Comorbid Conditions

4) By Distribution Channel: Direct Sales, Wholesalers and Distributors, Retail Pharmacies, Online Pharmacies

5) By End-User: Hospitals, Cardiovascular Clinics, Specialty Pharmacies, Home Healthcare Providers

Which Trends Are Affecting The Leqvio Market Framework?

Leading pharmaceutical firms are active in the Leqvio market, concentrating on the development of sophisticated injectable prescription drugs, utilizing strategies like Label Expansion to improve therapeutic access and facilitate earlier patient intervention. Label Expansion denotes the regulatory authorization provided by bodies like the FDA, permitting an existing approved medication to be utilized for new indications, different patient demographics, or in clinical contexts beyond its initial approval. As an illustration, in July 2023, the Swiss pharmaceutical company Novartis AG obtained approval from the US Food and Drug Administration (FDA) for an updated label for Leqvio (inclisiran). This update permits its administration at an earlier point for individuals with elevated LDL-C and a heightened risk of heart disease, alongside dietary changes and statin treatment. Administered with two doses per year following two initial doses, Leqvio achieves up to a 52% LDL-C reduction and has demonstrated efficacy for patients who cannot achieve their LDL-C goals even with statin therapy. The revised label emphasizes strong safety and effectiveness data, which was further substantiated by the VictORION clinical trial program.

Which Companies Are Influencing The Leqvio Market?

Major companies operating in the leqvio market are Novartis AG

Access The Complete Leqvio Market Report:

https://www.thebusinessresearchcompany.com/report/leqvio-global-market-report

Which Region Stands As The Largest Contributor To The Leqvio Market?

North America was the largest region in the leqvio market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the leqvio market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Expansion In Market Value Is Forecasted For The Leqvio Market Between 2026 And 2030?

Growth witnessed during the historic period resulted from the rising incidence of hyperlipidemia, breakthroughs in RNA interference technology, the ongoing expansion of cardiovascular specialty clinics, an increasing understanding of LDL cholesterol management, and enhancements in injectable drug delivery systems.

The anticipated expansion during the forecast timeframe stems from the wider acceptance of new RNA-based treatments, a heightened attention to mitigating cardiovascular risks, the development of therapies requiring less frequent administration, increased funding directed towards cardiometabolic studies, and a greater need for long-lasting cholesterol-reducing methods.

Key developments expected over the forecast horizon encompass a rise in the use of siRNA-based therapies to reduce lipids, a growing preference for cardiovascular therapies with extended effects, an intensifying emphasis on proactive heart care strategies, the broadening of sophisticated RNA production techniques, and a stronger focus on improving patient compliance with treatments.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20143&type=smp

What Key Factors Are Affecting The Leqvio Market Demand?

The increasing number of older adults is anticipated to fuel the demand for leqvio in the future. This demographic comprises people generally aged 65 years and older. Significant progress in healthcare and medical technology has notably extended life expectancy, thus expanding the geriatric demographic. Leqvio helps reduce LDL cholesterol, simplifying medication routines for senior citizens. Its prolonged action diminishes cardiovascular hazards, thereby improving health results among the elderly. For example, data from January 2024, provided by the Population Reference Bureau, a Kenya-based nonprofit, indicates that the count of Americans aged 65 and above is projected to rise from 58 million in 2022 to 82 million by 2050, representing a 47% increase. Concurrently, this cohort’s proportion of the total population is forecast to increase from 17% to 23% within the same timeframe. Consequently, the expanding geriatric population is a key catalyst for the leqvio market’s expansion.

Which Segments Define The Leqvio Market Segment Structure?

The leqvio market covered in this report is segmented –

1) By Formulation: Injectable Formulation (Subcutaneous), Pre-Filled Syringes Or Auto-Injectors

2) By Indication: Treatment Of Hyperlipidemia, Management Of Atherosclerotic Cardiovascular Disease (ASCVD), Treatment Of Familial Hypercholesterolemia

3) By Patient Demographics: Adult Patients, Geriatric Patients, Patients with Comorbid Conditions

4) By Distribution Channel: Direct Sales, Wholesalers and Distributors, Retail Pharmacies, Online Pharmacies

5) By End-User: Hospitals, Cardiovascular Clinics, Specialty Pharmacies, Home Healthcare Providers

What Emerging Trends Are Seen In The Leqvio Market?

Companies operating in the leqvio market are concentrating on the development of advanced injectable prescription medicines, including those requiring Label Expansion, to improve therapeutic accessibility and facilitate early intervention. Label Expansion denotes the regulatory authorization, typically from bodies like the FDA, permitting an already approved drug to be utilized for new indications, different patient demographics, or in varied clinical environments beyond its initial approval. As an illustration, in July 2023, Novartis AG, a pharmaceutical firm based in Switzerland, obtained US Food and Drug Administration (FDA) approval for an updated label for Leqvio (inclisiran). This update enables the drug’s administration at an earlier stage for individuals with elevated LDL-C and a heightened risk of heart disease, alongside diet and statin treatment. Following two initial doses, Leqvio requires two subsequent doses annually, offering up to a 52% reduction in LDL-C and demonstrating efficacy for patients who cannot achieve their LDL-C target even with statin therapy. The updated label underscores the strong safety and efficacy data, which was further substantiated by the VictORION clinical trial program.

Who Are The Established Players Within The Leqvio Market?

Major companies operating in the leqvio market are Novartis AG

Get The Full Leqvio Market Report:

https://www.thebusinessresearchcompany.com/report/leqvio-global-market-report

Where Is The Leqvio Market Primarily Concentrated By Region?

North America was the largest region in the leqvio market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the leqvio market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Leqvio Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/leqvio-global-market-report

Browse Through More Reports Similar to the Global Leqvio Market 2026, By The Business Research Company

Inductor Market Market Report 2026

https://www.thebusinessresearchcompany.com/report/inductor-market-global-market-report

Vertical Market Software Market Report 2026

https://www.thebusinessresearchcompany.com/report/vertical-market-software-global-market-report

Data Lake Market Report 2026

https://www.thebusinessresearchcompany.com/report/data-lake-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Valuation Is Forecasted For The Leqvio Market By 2030 Starting From Its 2026 Size?

Historical growth stemmed from a rising incidence of hyperlipidemia, alongside advancements in RNA interference technology, the expansion of cardiovascular specialty clinics, growing awareness regarding LDL cholesterol management, and improved injectable drug delivery systems.

The expansion throughout the projected timeframe is largely driven by the increasing integration of innovative RNA-based treatments, a heightened concentration on mitigating cardiovascular risks, the proliferation of therapies with extended dosing intervals, growing financial commitments to cardiometabolic investigations, and an escalating need for enduring lipid-reducing solutions.

Significant developments anticipated during the forecast period include a surge in the utilization of siRNA-based lipid-lowering treatments, an increasing desire for cardiovascular therapies offering prolonged effects, a greater commitment to strategies in preventive cardiology, the broadening of sophisticated RNA manufacturing processes, and a reinforced emphasis on improving patient compliance.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20143&type=smp

What Primary Drivers Are Shaping The Development Of The Leqvio Market?

The expanding geriatric demographic is anticipated to fuel the demand for leqvio in the future. This group comprises individuals typically 65 years and older, whose numbers are increasing due to notable progress in healthcare and medical technology, extending life expectancy. leqvio is particularly beneficial for older adults as it lowers LDL cholesterol, simplifying medication regimens, and its prolonged action mitigates cardiovascular risks, thereby improving health outcomes within this demographic. For instance, in January 2024, data from the Kenya-based nonprofit, Population Reference Bureau, indicated that the American population aged 65 and above is projected to surge from 58 million in 2022 to 82 million by 2050, representing a 47% rise. Concurrently, this age group’s proportion of the total population is also expected to climb from 17% to 23% over the identical timeframe. Consequently, the increasing geriatric population serves as a key impetus for the leqvio market’s expansion.

Which Segment Categories Define The Leqvio Market?

The leqvio market covered in this report is segmented –

1) By Formulation: Injectable Formulation (Subcutaneous), Pre-Filled Syringes Or Auto-Injectors

2) By Indication: Treatment Of Hyperlipidemia, Management Of Atherosclerotic Cardiovascular Disease (ASCVD), Treatment Of Familial Hypercholesterolemia

3) By Patient Demographics: Adult Patients, Geriatric Patients, Patients with Comorbid Conditions

4) By Distribution Channel: Direct Sales, Wholesalers and Distributors, Retail Pharmacies, Online Pharmacies

5) By End-User: Hospitals, Cardiovascular Clinics, Specialty Pharmacies, Home Healthcare Providers

What Major Market Trends Are Driving Changes In The Leqvio Market?

Leading companies active in the leqvio market are concentrating on developing advanced injectable prescription medications, such as those involving Label Expansion, to enhance therapeutic accessibility and facilitate early intervention. Label Expansion refers to the regulatory authorization granted by bodies, like the FDA, that permits an already approved drug to be used for additional indications, patient demographics, or clinical environments beyond its initial approved scope. For instance, in July 2023, Novartis AG, a Switzerland-based pharmaceutical company, received US Food and Drug Administration (FDA) approval for a label update for Leqvio (inclisiran), allowing its use at an earlier stage for patients with elevated LDL-C and an increased risk of heart disease, in addition to diet and statin therapy. Administered as two doses per year after two initial doses, it offers up to a 52% LDL-C reduction and has proven effective for patients unable to reach their LDL-C target despite statin therapy. This label update underscores robust safety and efficacy data, which was reinforced by the VictORION clinical trial program.

Who Are The Top Companies Competing In The Leqvio Market?

Major companies operating in the leqvio market are Novartis AG

Read the full leqvio market report here:

https://www.thebusinessresearchcompany.com/report/leqvio-global-market-report

How Does The Leqvio Market Perform Across Major Global Regions?

North America was the largest region in the leqvio market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the leqvio market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Leqvio Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20143&type=smp

Browse Through More Reports Similar to the Global Leqvio Market 2026, By The Business Research Company

Inductor Market Market Report 2026

https://www.thebusinessresearchcompany.com/report/inductor-market-global-market-report

Vertical Market Software Market Report 2026

https://www.thebusinessresearchcompany.com/report/vertical-market-software-global-market-report

Data Lake Market Report 2026

https://www.thebusinessresearchcompany.com/report/data-lake-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Valuation Is Forecasted For The Leqvio Market By 2030 Starting From Its 2026 Size?

Historical growth stemmed from a rising incidence of hyperlipidemia, alongside advancements in RNA interference technology, the expansion of cardiovascular specialty clinics, growing awareness regarding LDL cholesterol management, and improved injectable drug delivery systems.

The expansion throughout the projected timeframe is largely driven by the increasing integration of innovative RNA-based treatments, a heightened concentration on mitigating cardiovascular risks, the proliferation of therapies with extended dosing intervals, growing financial commitments to cardiometabolic investigations, and an escalating need for enduring lipid-reducing solutions.

Significant developments anticipated during the forecast period include a surge in the utilization of siRNA-based lipid-lowering treatments, an increasing desire for cardiovascular therapies offering prolonged effects, a greater commitment to strategies in preventive cardiology, the broadening of sophisticated RNA manufacturing processes, and a reinforced emphasis on improving patient compliance.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20143&type=smp

What Primary Drivers Are Shaping The Development Of The Leqvio Market?

The expanding geriatric demographic is anticipated to fuel the demand for leqvio in the future. This group comprises individuals typically 65 years and older, whose numbers are increasing due to notable progress in healthcare and medical technology, extending life expectancy. leqvio is particularly beneficial for older adults as it lowers LDL cholesterol, simplifying medication regimens, and its prolonged action mitigates cardiovascular risks, thereby improving health outcomes within this demographic. For instance, in January 2024, data from the Kenya-based nonprofit, Population Reference Bureau, indicated that the American population aged 65 and above is projected to surge from 58 million in 2022 to 82 million by 2050, representing a 47% rise. Concurrently, this age group’s proportion of the total population is also expected to climb from 17% to 23% over the identical timeframe. Consequently, the increasing geriatric population serves as a key impetus for the leqvio market’s expansion.

Which Segment Categories Define The Leqvio Market?

The leqvio market covered in this report is segmented –

1) By Formulation: Injectable Formulation (Subcutaneous), Pre-Filled Syringes Or Auto-Injectors

2) By Indication: Treatment Of Hyperlipidemia, Management Of Atherosclerotic Cardiovascular Disease (ASCVD), Treatment Of Familial Hypercholesterolemia

3) By Patient Demographics: Adult Patients, Geriatric Patients, Patients with Comorbid Conditions

4) By Distribution Channel: Direct Sales, Wholesalers and Distributors, Retail Pharmacies, Online Pharmacies

5) By End-User: Hospitals, Cardiovascular Clinics, Specialty Pharmacies, Home Healthcare Providers

What Major Market Trends Are Driving Changes In The Leqvio Market?

Leading companies active in the leqvio market are concentrating on developing advanced injectable prescription medications, such as those involving Label Expansion, to enhance therapeutic accessibility and facilitate early intervention. Label Expansion refers to the regulatory authorization granted by bodies, like the FDA, that permits an already approved drug to be used for additional indications, patient demographics, or clinical environments beyond its initial approved scope. For instance, in July 2023, Novartis AG, a Switzerland-based pharmaceutical company, received US Food and Drug Administration (FDA) approval for a label update for Leqvio (inclisiran), allowing its use at an earlier stage for patients with elevated LDL-C and an increased risk of heart disease, in addition to diet and statin therapy. Administered as two doses per year after two initial doses, it offers up to a 52% LDL-C reduction and has proven effective for patients unable to reach their LDL-C target despite statin therapy. This label update underscores robust safety and efficacy data, which was reinforced by the VictORION clinical trial program.

Who Are The Top Companies Competing In The Leqvio Market?

Major companies operating in the leqvio market are Novartis AG

Read the full leqvio market report here:

https://www.thebusinessresearchcompany.com/report/leqvio-global-market-report

How Does The Leqvio Market Perform Across Major Global Regions?

North America was the largest region in the leqvio market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the leqvio market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Leqvio Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20143&type=smp

Browse Through More Reports Similar to the Global Leqvio Market 2026, By The Business Research Company

Inductor Market Market Report 2026

https://www.thebusinessresearchcompany.com/report/inductor-market-global-market-report

Vertical Market Software Market Report 2026

https://www.thebusinessresearchcompany.com/report/vertical-market-software-global-market-report

Data Lake Market Report 2026

https://www.thebusinessresearchcompany.com/report/data-lake-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Valuation Is Forecasted For The Leqvio Market By 2030 Starting From Its 2026 Size?

Historical growth stemmed from a rising incidence of hyperlipidemia, alongside advancements in RNA interference technology, the expansion of cardiovascular specialty clinics, growing awareness regarding LDL cholesterol management, and improved injectable drug delivery systems.

The expansion throughout the projected timeframe is largely driven by the increasing integration of innovative RNA-based treatments, a heightened concentration on mitigating cardiovascular risks, the proliferation of therapies with extended dosing intervals, growing financial commitments to cardiometabolic investigations, and an escalating need for enduring lipid-reducing solutions.

Significant developments anticipated during the forecast period include a surge in the utilization of siRNA-based lipid-lowering treatments, an increasing desire for cardiovascular therapies offering prolonged effects, a greater commitment to strategies in preventive cardiology, the broadening of sophisticated RNA manufacturing processes, and a reinforced emphasis on improving patient compliance.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20143&type=smp

What Primary Drivers Are Shaping The Development Of The Leqvio Market?

The expanding geriatric demographic is anticipated to fuel the demand for leqvio in the future. This group comprises individuals typically 65 years and older, whose numbers are increasing due to notable progress in healthcare and medical technology, extending life expectancy. leqvio is particularly beneficial for older adults as it lowers LDL cholesterol, simplifying medication regimens, and its prolonged action mitigates cardiovascular risks, thereby improving health outcomes within this demographic. For instance, in January 2024, data from the Kenya-based nonprofit, Population Reference Bureau, indicated that the American population aged 65 and above is projected to surge from 58 million in 2022 to 82 million by 2050, representing a 47% rise. Concurrently, this age group’s proportion of the total population is also expected to climb from 17% to 23% over the identical timeframe. Consequently, the increasing geriatric population serves as a key impetus for the leqvio market’s expansion.

Which Segment Categories Define The Leqvio Market?

The leqvio market covered in this report is segmented –

1) By Formulation: Injectable Formulation (Subcutaneous), Pre-Filled Syringes Or Auto-Injectors

2) By Indication: Treatment Of Hyperlipidemia, Management Of Atherosclerotic Cardiovascular Disease (ASCVD), Treatment Of Familial Hypercholesterolemia

3) By Patient Demographics: Adult Patients, Geriatric Patients, Patients with Comorbid Conditions

4) By Distribution Channel: Direct Sales, Wholesalers and Distributors, Retail Pharmacies, Online Pharmacies

5) By End-User: Hospitals, Cardiovascular Clinics, Specialty Pharmacies, Home Healthcare Providers

What Major Market Trends Are Driving Changes In The Leqvio Market?

Leading companies active in the leqvio market are concentrating on developing advanced injectable prescription medications, such as those involving Label Expansion, to enhance therapeutic accessibility and facilitate early intervention. Label Expansion refers to the regulatory authorization granted by bodies, like the FDA, that permits an already approved drug to be used for additional indications, patient demographics, or clinical environments beyond its initial approved scope. For instance, in July 2023, Novartis AG, a Switzerland-based pharmaceutical company, received US Food and Drug Administration (FDA) approval for a label update for Leqvio (inclisiran), allowing its use at an earlier stage for patients with elevated LDL-C and an increased risk of heart disease, in addition to diet and statin therapy. Administered as two doses per year after two initial doses, it offers up to a 52% LDL-C reduction and has proven effective for patients unable to reach their LDL-C target despite statin therapy. This label update underscores robust safety and efficacy data, which was reinforced by the VictORION clinical trial program.

Who Are The Top Companies Competing In The Leqvio Market?

Major companies operating in the leqvio market are Novartis AG

Read the full leqvio market report here:

https://www.thebusinessresearchcompany.com/report/leqvio-global-market-report

How Does The Leqvio Market Perform Across Major Global Regions?

North America was the largest region in the leqvio market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the leqvio market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Leqvio Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20143&type=smp

Browse Through More Reports Similar to the Global Leqvio Market 2026, By The Business Research Company

Inductor Market Market Report 2026

https://www.thebusinessresearchcompany.com/report/inductor-market-global-market-report

Vertical Market Software Market Report 2026

https://www.thebusinessresearchcompany.com/report/vertical-market-software-global-market-report

Data Lake Market Report 2026

https://www.thebusinessresearchcompany.com/report/data-lake-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the leqvio market from 2026–2035 with trusted insights from The Business Research Company

What total market size is anticipated for the Leqvio Market in 2030?

Historical growth was largely driven by the increasing occurrence of hyperlipidemia, alongside advancements in RNA interference technology, the expansion of cardiovascular specialty clinics, a heightened awareness of LDL cholesterol management, and improved injectable drug delivery systems.

Anticipated market expansion over the forecast period is propelled by the escalating uptake of innovative RNA therapeutics, a heightened emphasis on mitigating cardiovascular risks, the broader availability of therapies with extended dosing intervals, increased capital allocation for cardiometabolic investigations, and a rising requirement for sustainable lipid-reducing interventions.

Significant trends expected during the forecast period encompass the increasing integration of siRNA-based lipid-reducing treatments, an escalating desire for cardiovascular therapies offering prolonged effects, a concentrated effort on developing preventative cardiology approaches, the advancement of sophisticated RNA production techniques, and a stronger commitment to optimizing patient treatment adherence.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20143&type=smp

What Drivers Are Influencing Production Trends In The Leqvio Market?

The increasing number of older adults is anticipated to propel the demand for leqvio in the future. This demographic segment typically includes individuals 65 years of age and older. Significant improvements in healthcare and medical advancements have substantially extended life expectancy, thereby fueling the expansion of the geriatric demographic. Leqvio is effective in reducing LDL cholesterol, simplifying medication regimens for elderly patients. Its extended duration of action diminishes cardiovascular hazards, thereby improving health results for older individuals. As an illustration, data from January 2024, provided by the Kenya-based nonprofit, the Population Reference Bureau, indicates that the count of Americans aged 65 and above is projected to rise from 58 million in 2022 to 82 million by 2050, marking a 47% increase. Concurrently, this demographic’s proportion of the total population is also forecast to increase from 17% to 23% over the identical timeframe. Consequently, the expanding geriatric populace is a key factor propelling the expansion of the leqvio market.

Which Segments Are Gaining Traction In The Leqvio Market?

The leqvio market covered in this report is segmented –

1) By Formulation: Injectable Formulation (Subcutaneous), Pre-Filled Syringes Or Auto-Injectors

2) By Indication: Treatment Of Hyperlipidemia, Management Of Atherosclerotic Cardiovascular Disease (ASCVD), Treatment Of Familial Hypercholesterolemia

3) By Patient Demographics: Adult Patients, Geriatric Patients, Patients with Comorbid Conditions

4) By Distribution Channel: Direct Sales, Wholesalers and Distributors, Retail Pharmacies, Online Pharmacies

5) By End-User: Hospitals, Cardiovascular Clinics, Specialty Pharmacies, Home Healthcare Providers

What Trends Are Reshaping The Dynamics Of The Leqvio Market?

Leading companies are active in the leqvio market, concentrating on creating sophisticated injectable prescription drugs, for example, through Label Expansion, to improve therapeutic reach and prompt intervention. Label Expansion signifies regulatory authorization from bodies like the FDA, enabling an already approved medication to be utilized for new indications, patient demographics, or clinical contexts beyond its initial authorization. As an illustration, in July 2023, Novartis AG, a pharmaceutical firm based in Switzerland, secured US Food and Drug Administration (FDA) approval for an updated label for Leqvio (inclisiran), permitting its application earlier for individuals having high LDL-C and a higher propensity for heart disease, alongside diet and statin therapy. Administered with two doses per year following two initial doses, it delivers up to a 52% LDL-C reduction and has demonstrated efficacy for patients struggling to achieve their LDL-C target even with statin therapy. This label update underscores strong safety and efficacy data, which was further supported by the VictORION clinical trial program.

Who Are The Major Companies Operating In The Leqvio Market?

Major companies operating in the leqvio market are Novartis AG

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/leqvio-global-market-report

Which Region Is Anticipated To See The Fastest Growth In The Leqvio Market?

North America was the largest region in the leqvio market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the leqvio market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Leqvio Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20143&type=smp

Browse Through More Reports Similar to the Global Leqvio Market 2026, By The Business Research Company

Inductor Market Market Report 2026

https://www.thebusinessresearchcompany.com/report/inductor-market-global-market-report

Vertical Market Software Market Report 2026

https://www.thebusinessresearchcompany.com/report/vertical-market-software-global-market-report

Data Lake Market Report 2026

https://www.thebusinessresearchcompany.com/report/data-lake-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Fast Is The Leqvio Market Expected to Grow Between 2025 And 2029?

The scale of the leqvio market has expanded by XX (HCAGR) in the last few years. It’s projected to surge from $XX million in 2024 to $XX million in 2025, with a compound annual growth rate (CAGR) of XX%. This growth during the historic phase can be associated with several factors like the surge in funding for RNA-based drug creation, heightened expenditure on cholesterol control drugs, escalation in R&D and medicine development investments, improved awareness in healthcare, and the growing requirement for specialized medicines.

What Growth Rate Is Anticipated for the Leqvio Market in the Coming Years?

The market size of leqvio is anticipated to witness an XX (FCAGR) surge in the following years, escalating to a value of $XX million by 2029, with a compound annual growth rate (CAGR) of XX%. The predicted growth during the forecast period could be due to the increasing global instances of cardiovascular diseases, heightened awareness about the potency of PCSK9 inhibitors, a rise in high cholesterol cases, an ageing population, and expansion of biologic drugs. Notable trends in the forecast period encompass an escalating demand for enhanced hypercholesterolemia treatments, broader implications resulting from continued research, ongoing sanctioning from regulatory agencies like the FDA, advancements in biopharmaceutical research, and progressive drug development.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20143&type=smp

Who Are the Leading Companies in the Leqvio Market?

Major companies operating in the leqvio market include Novartis AG

What Are the Key Drivers of the Leqvio Market?

Growth within the Leqvio market is being spurred on by a rise in instances of cardiovascular diseases. Cardiovascular complications, which typically comprise heart-caused issues such as strokes, heart attacks, and high blood pressure, impact the blood vessels and heart. Several factors, such as an unhealthy diet, physical inactivity, ageing, diabetes, and high alcohol consumption contribute to the onset of these diseases. Leqvio aids in lowering LDL levels and reducing the risk of cardiovascular events by blocking the PCSK9 protein, which in turn boosts the liver’s capacity to clear LDL cholesterol from the bloodstream. To illustrate, data from the British Heart Foundation released in September 2024 confirms that heart and circulatory diseases affect around 7.6 million people in the UK, inclusive of close to 4 million males and about 3.6 million females. These diseases account for approximately 27% of all deaths in the UK, equating to an annual death toll of over 170,000, or an average of 480 deaths daily. This figures to one death every three minutes. Therefore, the escalating prevalence of cardiovascular diseases is fuelling the expansion of the Leqvio market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=20143&type=smp

What Are the Key Market Segments in the Leqvio Industry?

The leqvio market covered in this report is segmented –

1) By Formulation: Injectable Formulation (Subcutaneous), Pre-Filled Syringes Or Auto-Injectors

2) By Indication: Treatment Of Hyperlipidemia, Management Of Atherosclerotic Cardiovascular Disease (ASCVD), Treatment Of Familial Hypercholesterolemia

3) By Patient Demographics: Adult Patients, Geriatric Patients, Patients with Comorbid Conditions

4) By Distribution Channel: Direct Sales, Wholesalers and Distributors, Retail Pharmacies, Online Pharmacies

5) By End-User: Hospitals, Cardiovascular Clinics, Specialty Pharmacies, Home Healthcare Providers

What Are the Latest Trends in the Leqvio Market?

The primary trend in the leqvio market revolves around the development of advanced injectable prescription drugs aimed at offering durable treatments that enhance patient compliance and results. These injectable prescription drugs, which aim to control high cholesterol levels and mitigate cardiovascular risks, are typically administered at consistent intervals to maintain their therapeutic influence. As an example, in July 2023, Novartis, a pharmaceutical organization based in Switzerland, was granted approval from the US Food and Drug Administration (FDA) for a label update for Leqvio (inclisiran). This approval permitted Leqvio’s use at earlier stages for patients with elevated LDL-C levels and a heightened risk of cardiac disease, in combination with diet and statin therapy. Administered twice a year following two initial doses, it leads to a reduction in LDL-C levels by up to 52% and proves effective for patients who can’t achieve their LDL-C goals despite undergoing statin therapy. The VictORION clinical trial program validated the safety and effectiveness encapsulated in the label update.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/leqvio-global-market-report

What Are the Key Regional Markets in the Leqvio Industry?

North America was the largest region in the leqvio market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the leqvio market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20143

This Report Delivers Insight On:

1. How big is the leqvio market, and how is it changing globally?

2. Who are the major companies in the leqvio market, and how are they performing?

3. What are the key opportunities and risks in the leqvio market right now?

4. Which products or customer segments are growing the most in the leqvio market?

5. What factors are helping or slowing down the growth of the leqvio market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Discover trends, market shifts, and competitive outlooks for the leqvio global market report 2025 industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

What is the Projected CAGR for the Leqvio Market Size from 2025 to 2034?

In recent times, the leqvio market has seen an XX (HCAGR). It is forecasted to expand from $XX million in 2024 to $XX million in 2025, exhibiting a compound annual growth rate (CAGR) of XX%. This development throughout the historic period is linked to an upsurge in financing for RNA-based drug development, heightened expenditure on medications for cholesterol management, an increase in R&D investment and medication development, improved healthcare awareness, and a growing demand for specialized medicines.

In the coming years, the market size for leqvio is projected to observe an FCAGR of XX. By 2029, it is anticipated to expand to a market worth of $XX million, with a compound annual growth rate (CAGR) of XX%. The interested period’s expansion is linked to the escalating global rate of cardiovascular diseases, enhanced cognizance of the potency of PCSK9 inhibitors, rise in high cholesterol incidents, increase in the elderly population, and biologic drugs’ evolution. The forecasted era will witness major trends like growing preference for advanced hypercholesterolemia treatments, broadened indications via continuous research, successive approvals from regulatory platforms such as FDA, breakthroughs in biopharmaceutical studies, and drug development advancements.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20143&type=smp

What Are the Core Market Drivers Propelling Growth in the Leqvio Industry?

The anticipated expansion of the leqvio market is largely due to the growing instances of cardiovascular diseases. These diseases – affecting the heart and blood vessels – often lead to severe consequences such as heart attacks, strokes, and hypertension. The rise in these conditions is generally attributed to unhealthy eating habits, lack of physical activity, overconsumption of alcohol, diabetes, and advancing age. Leqvio, works by inhibiting the PCSK9 protein, which bolsters the liver’s function in eliminating LDL cholesterol from our bloodstream. This process essentially reduces LDL levels, lessening the likelihood of heart attacks, strokes, and other related cardiovascular incidents. To exemplify, data published by the British Heart Foundation in September 2024, a cardiovascular research non-profit based in the UK, stated that around 7.6 million individuals in the UK suffer from heart and circulatory diseases. Among these, approximately 4 million are male and 3.6 million are female. Such diseases account for nearly 27% of all deaths in the UK, leading to more than 170,000 fatalities per annum or about 480 per day, translating to one death every three minutes. As such, the mounting cases of cardiovascular diseases are fueling the growth of the Leqvio market.

How Is the Leqvio Market Segmented?

The leqvio market covered in this report is segmented –

1) By Formulation: Injectable Formulation (Subcutaneous), Pre-Filled Syringes Or Auto-Injectors

2) By Indication: Treatment Of Hyperlipidemia, Management Of Atherosclerotic Cardiovascular Disease (ASCVD), Treatment Of Familial Hypercholesterolemia

3) By Patient Demographics: Adult Patients, Geriatric Patients, Patients with Comorbid Conditions

4) By Distribution Channel: Direct Sales, Wholesalers and Distributors, Retail Pharmacies, Online Pharmacies

5) By End-User: Hospitals, Cardiovascular Clinics, Specialty Pharmacies, Home Healthcare Providers

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=20143&type=smp

Which Regions Are Driving the Next Phase of the Leqvio Market Growth?

North America was the largest region in the leqvio market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the leqvio market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

What Key Market Trends and Innovations Are Shaping the Future of the Leqvio Industry?

The primary trend in the Leqvio market revolves around the innovation and progression of advanced injectable prescription medication. This aims at providing long-term treatments, bolstering patient compliance and improving results. These injectable prescription medications are administered through injections, primarily intended for managing high cholesterol levels and minimizing cardiovascular threats. Therapy is generally offered at consistent intervals to maintain an enduring therapeutic influence. An example of this was in July 2023 when Novartis, a Swiss firm specializing in pharmaceuticals, gained approval for a label update for Leqvio (inclisiran) from the US FDA. This approval allowed the early use of the medicine in patients with high LDL-C and a heightened risk of cardiac disease, supplementing diet and statin therapy. Administered as two initial doses, followed by two doses annually, Leqvio is documented to reduce LDL-C levels by 52% and is shown to be effective for patients who fail to achieve their LDL-C objectives despite statin therapy. The label update underscores the comprehensive safety and efficacy data, as reinforced through the VictORION clinical trial program.

View the full report here:

https://www.thebusinessresearchcompany.com/report/leqvio-global-market-report

How Is the Leqvio Market Defined and What Are Its Core Parameters?

Leqvio is an siRNA-based therapy that reduces low-density lipoprotein (LDL) cholesterol by silencing the mRNA responsible for PCSK9 production in the liver. It improves the liver’s ability to clear LDL-C from the bloodstream, lowering the risk of heart attacks, strokes, and other cardiovascular events in high-risk patients.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20143

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model